ERBB2 and cancer: In this study, we proposed a novel Herceptin-mediated NK activation method to amplify NK cells with considerably lower dose of Herceptin pretreatment in vitro which displayed significantly enhanced cytotoxicity against HER2-positive breast cancer cells and proposed an alternative solution for cancer patients resistant to conventional Herceptin treatment.